Advancements in nanotechnology-based drug delivery systems are also progressing, particularly with the development of pH-sensitive carriers aimed at enhancing the targeted release of VEGFR inhibitors within the tumor microenvironment, thereby potentially reducing systemic toxicity (22). The gene discussed is KDR; the disease is neoplasm.